Roth Capital Starts Cell Therapeutics (CTIC) at Buy
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Roth Capital initiates coverage on Cell Therapeutics (NASDAQ: CTIC) with a Buy. PT $4.00.
For an analyst ratings summary and ratings history on Cell Therapeutics click here. For more ratings news on Cell Therapeutics click here.
Shares of Cell Therapeutics closed at $1.54 yesterday.
For an analyst ratings summary and ratings history on Cell Therapeutics click here. For more ratings news on Cell Therapeutics click here.
Shares of Cell Therapeutics closed at $1.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
- Cantor Fitzgerald Starts Materialise NV (MTLS) at Overweight, 'Well-Positioned to meet rising software demand'
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
